Episode
Obakulactone Targets ACOT1 to Fight Arthritis | Health and Fitness News
- Published
- Jul 23, 2026
- Duration seconds
- 99
- Processing state
not_requested- Canonical source
- https://sources.thednn.ai/782f7f247b4b28d0
Actions
POST https://stenobird.com/v1/public/podcasts/health-news-today-2-min-news-the-daily-news-now-7685759/episodes/obakulactone-targets-acot1-to-fight-arthritis-health-and-fitness-news/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/health-news-today-2-min-news-the-daily-news-now-7685759/obakulactone-targets-acot1-to-fight-arthritis-health-and-fitness-news.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
A breakthrough discovery could soon offer new hope for rheumatoid arthritis sufferers: scientists have identified obakulactone (OL), a compound from traditional Chinese medicine, as a powerful anti-inflammatory agent. OL works by targeting the protein ACOT1 and rebalancing harmful fats in the body, effectively calming the inflammation that ravages joints. In rat studies, OL dramatically reduced swelling, repaired cartilage, and even restored immune organ health. It also slashed key inflammatory markers like IL-6 and TNF-alpha. This deep molecular insight not only reveals OL’s mechanism but also highlights ACOT1 as a promising new drug target — potentially paving the way for smarter, more effective RA treatments. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/782f7f247b4b28d0